News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
70,000 Results
Type
Article (1932)
Company Profile (2)
Press Release (68066)
Section
Business (21466)
Career Advice (9)
Deals (4553)
Drug Development (8165)
FDA (1806)
Job Trends (800)
News (37029)
Policy (3567)
Tag
Academia (93)
Allergies (5)
Alliances (8137)
ALS (6)
Alzheimer's disease (123)
Antibody-drug conjugate (ADC) (13)
Approvals (1837)
Artificial intelligence (14)
Automation (1)
Bankruptcy (8)
Best Places to Work (585)
Biosimilars (22)
Biotechnology (5)
Bladder cancer (11)
Brain cancer (2)
Breast cancer (21)
Cancer (220)
Cardiovascular disease (5)
Career advice (9)
CAR-T (4)
Cell therapy (25)
Clinical research (7037)
Collaboration (94)
Compensation (9)
Complete response letters (2)
COVID-19 (188)
C-suite (16)
Cystic fibrosis (4)
Data (201)
Depression (1)
Diabetes (14)
Diagnostics (600)
Digital health (1)
Drug discovery (13)
Duchenne muscular dystrophy (12)
Earnings (7638)
Events (7006)
Executive appointments (49)
FDA (1956)
Featured Employer (1)
Fibrodysplasia Ossificans Progressiva (1)
Funding (60)
Gene editing (3)
Gene therapy (19)
GLP-1 (45)
Government (235)
Grass and pollen (1)
Guidances (4)
Healthcare (1078)
IgA nephropathy (4)
Immunology and inflammation (1)
Indications (3)
Infectious disease (195)
Inflammatory bowel disease (17)
Influenza (6)
Intellectual property (17)
IPO (1626)
Job creations (241)
Job search strategy (9)
Layoffs (6)
Legal (953)
Liver cancer (16)
Lung cancer (36)
Lymphoma (14)
Manufacturing (31)
MASH (7)
Medical device (1123)
Medtech (1124)
Mergers & acquisitions (3024)
Metabolic disorders (39)
Multiple sclerosis (8)
NASH (1)
Neurodegenerative disease (7)
Neuroscience (168)
NextGen: Class of 2025 (219)
Non-profit (61)
Northern California (138)
Obesity (16)
Opinion (1)
Ovarian cancer (10)
Pain (4)
Pancreatic cancer (8)
Parkinson's disease (15)
Partnered (2)
Patents (19)
Patient recruitment (8)
People (4968)
Pharmaceutical (3)
Phase I (1913)
Phase II (2952)
Phase III (2666)
Pipeline (125)
Postmarket research (242)
Preclinical (669)
Press Release (2)
Prostate cancer (8)
Radiopharmaceuticals (22)
Rare diseases (27)
Real estate (600)
Regulatory (2607)
Reports (6)
Research institute (92)
Schizophrenia (7)
Series A (15)
Series B (7)
Service/supplier (1)
Sickle cell disease (1)
Southern California (161)
Spinal muscular atrophy (4)
Startups (422)
Stomach cancer (1)
Supply chain (8)
United States (1325)
Vaccines (24)
Venture capitalists (2)
Weight loss (2)
Women's health (1)
Date
Today (13)
Last 7 days (68)
Last 30 days (219)
Last 365 days (2924)
2025 (890)
2024 (3253)
2023 (3814)
2022 (7016)
2021 (6373)
2020 (5876)
2019 (3875)
2018 (3012)
2017 (3561)
2016 (3174)
2015 (4030)
2014 (3020)
2013 (2600)
2012 (2776)
2011 (2902)
2010 (2663)
Location
Africa (79)
Alabama (1)
Arizona (8)
Asia (21398)
Australia (2433)
California (351)
Canada (225)
China (165)
Colorado (4)
Connecticut (14)
Delaware (4)
Europe (12476)
Florida (22)
Georgia (7)
Illinois (16)
India (11)
Indiana (4)
Japan (82)
Kansas (5)
Louisiana (1)
Maine (4)
Maryland (75)
Massachusetts (243)
Michigan (2)
Minnesota (27)
Missouri (3)
Nebraska (1)
Nevada (1)
New Jersey (201)
New York (148)
North Carolina (61)
Northern California (138)
Ohio (2)
Oregon (1)
Pennsylvania (54)
South America (106)
Southern California (161)
Tennessee (1)
Texas (28)
Utah (13)
Virginia (25)
Washington D.C. (2)
Washington State (17)
Wisconsin (6)
70,000 Results for "kamada ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kamada Declares Special Cash Dividend of $0.20 Per Share
March 6, 2025
·
6 min read
Press Releases
Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas
March 20, 2025
·
6 min read
Press Releases
Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025
February 27, 2025
·
2 min read
Business
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Kamada Ltd. announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024.
May 1, 2024
·
2 min read
Press Releases
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America
January 23, 2025
·
9 min read
Pharm Country
Kamada Issues 2024 CEO Letter to Shareholders
Kamada Ltd., a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, issued a Letter to Shareholders from Amir London, Chief Executive Officer.
March 6, 2024
·
18 min read
Press Releases
Kamada to Present at the Stifel 2024 Healthcare Conference
November 5, 2024
·
3 min read
Press Releases
Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025
January 9, 2025
·
11 min read
Business
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
Kamada Ltd. announced financial results for the three months and year ended December 31, 2023.
March 6, 2024
·
21 min read
Business
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
Kamada Ltd., a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced financial results for three months ended March 31, 2024.
May 8, 2024
·
18 min read
1 of 7,000
Next
